L'intérêt à découvert pour Pacific Biosciences donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Pacific Biosciences. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Pacific Biosciences (NASDAQ:PACB) Stock, Rapport sur les intérêts à découvert

Pacific Biosciences

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Pacific Biosciences of California, Inc. - Common Stock

Pacific Biosciences of California Inc

PACIFIC BIOSCIENCES OF CALIFRNIA ORD

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 350 points on Friday.
The Dow traded up 0.86% to 42,820.94 while the NASDAQ rose 0.35% to 18,346.63. The S&amp;P 500 also rose, gaining, 0.58% to 5,813.55.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/10/41290375/how-to-earn-500-a-month-from-bank-of-america-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Bank of America Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Financials shares jumped by 1.9% on Friday.
In trading on Friday, consumer discretionary shares fell by 0.3%.
Top Headline
BlackRock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) reported better-than-expected third-quarter results.
Revenue growth of 15% Y/Y to $5.197 billion, beating the consensus of $5.007 billion. Adjusted EPS increased 5% Y/Y to $11.46, beating the consensus of $10.38.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Top Wealth Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) shares shot up 194% to $6.21. The company priced its $10.8 million public offering of 27 million ordinary shares at $0.40 per share.</li>
<li>Shares of Pacific Biosciences of California Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) got a boost, surging 30% to $2.0093 after the company announced it signed a research collaboration agreement with the National Cancer Center of Singapore. The project will use the company&#8217;s sequencing technologies.</li>
<li>Conduit Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares were also up, gaining 9% to $0.1119 after AstraZeneca reported a 9.9% stake in the company.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares dropped 8% to $218.97 following its Cybercab unveiling, with investors assessing a potential 2026 or 2027 timeline.</li>
<li>Shares of Perspective Therapeutics Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NYSE">CATX</a>) were down 8% to $12.20. Perspective Therapeutics announced plans to advance development of radiopharmaceutical therapy [212Pb]VMT01 after data at Society for Melanoma Research Congress.</li>
<li>A. O. Smith Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>) was down, falling 7% to $80.33 after the company reported preliminary third-quarter results below estimates and cut its FY24 EPS guidance below estimates.</li>
</ul>
Commodities In commodity news, oil traded down 0.5% to $75.49 while gold traded up 1.3% at $2,673.40.
Silver traded up 1.4% to $31.675 on Friday, while copper rose 1.4% to $4.4875.
Euro zone
European shares closed higher today. The eurozone's STOXX 600 gained 0.55%, Germany's DAX gained 0.85% and France's CAC 40 rose 0.48%. Spain's IBEX 35 Index rose 0.54%, while London's FTSE 100 rose 0.19%.
The UK&#8217;s trade deficit shrank to £0.96 billion in August compared to a revised £4.71 billion gap in July, while the British economy grew by 0.2% month-over-month in August. Industrial production in the UK climbed 0.5% month-over-month in August. The annual inflation rate in Germany fell to 1.6% in September from 1.9% in August
Asia Pacific Markets
Asian markets closed mixed on Friday, with Japan's Nikkei 225 gaining 0.57%, China's Shanghai Composite Index dipping 2.55% and India's BSE Sensex falling 0.28%.
Industrial production in India fell 0.1% year-over-year in August compared to a revised 4.7% gain in July.
Economics
<ul>
<li>Core producer prices in the U.S. increased by 0.2% from the previous month for September compared to a 0.3% rise in August.</li>
<li>The University of Michigan consumer sentiment fell to 68.9 in October versus a five-month high level of 70.1 in September, and compared to market estimates of 70.8.</li>
<li>The total number of active U.S. oil rigs rose by two to 481 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41290782/cvs-has-real-value-jim-cramer-says-micron-had-an-amazing-quarter"> CVS Has &#8216;Real Value,&#8217; Jim Cramer Says: Micron Had An &#8216;Amazing&#8217; Quarter</a></li>
</ul>

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

CATX

PACB

TSLA

S&P 500 Moves Higher; BlackRock Reports Upbeat Results

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 250 points on Friday.
The Dow traded up 0.63% to 42,722.78 while the NASDAQ rose 0.14% to 18,306.94. The S&amp;P 500 also rose, gaining, 0.39% to 5,802.82.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/10/41290375/how-to-earn-500-a-month-from-bank-of-america-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Bank of America Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Financials shares jumped by 2% on Friday.
In trading on Friday, consumer discretionary shares rose by just 0.1%.
Top Headline
Shares of Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) gained more than 5% on Friday after the company reported better-than-expected earnings for its third quarter.
It reported a GAAP EPS of $1.42, beating the consensus of $1.28. Revenue fell 2% to $20.37 billion. Analysts expected $20.41 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Top Wealth Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) shares shot up 156% to $5.40. The company priced its $10.8 million public offering of 27 million ordinary shares at $0.40 per share.</li>
<li>Shares of Pacific Biosciences of California Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) got a boost, surging 14% to $1.76 after the company announced it signed a research collaboration agreement with the National Cancer Center of Singapore. The project will use the company&#8217;s sequencing technologies.</li>
<li>Conduit Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares were also up, gaining 44% to $0.1472 after AstraZeneca reported a 9.9% stake in the company.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares dropped 8% to $220.01 following its Cybercab unveiling, with investors assessing a potential 2026 or 2027 timeline.</li>
<li>Shares of Perspective Therapeutics Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NYSE">CATX</a>) were down 15% to $11.32. Perspective Therapeutics announced plans to advance development of radiopharmaceutical therapy [212Pb]VMT01 after data at Society for Melanoma Research Congress.</li>
<li>A. O. Smith Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>) was down, falling 6% to $81.42 after the company reported preliminary third-quarter results below estimates and cut its FY24 EPS guidance below estimates.</li>
</ul>
Commodities In commodity news, oil traded down 0.5% to $75.44 while gold traded up 1.1% at $2,667.70.
Silver traded up 1.5% to $31.705 on Friday, while copper rose 1.1% to $4.4780.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.61%, Germany's DAX gained 0.77% and France's CAC 40 rose 0.61%. Spain's IBEX 35 Index rose 0.56%, while London's FTSE 100 rose 0.29%.
The UK&#8217;s trade deficit shrank to £0.96 billion in August compared to a revised £4.71 billion gap in July, while the British economy grew by 0.2% month-over-month in August. Industrial production in the UK climbed 0.5% month-over-month in August. The annual inflation rate in Germany fell to 1.6% in September from 1.9% in August
Asia Pacific Markets
Asian markets closed mixed on Friday, with Japan's Nikkei 225 gaining 0.57%, China's Shanghai Composite Index dipping 2.55% and India's BSE Sensex falling 0.28%.
Industrial production in India fell 0.1% year-over-year in August compared to a revised 4.7% gain in July.
Economics
<ul>
<li>Core producer prices in the U.S. increased by 0.2% from the previous month for September compared to a 0.3% rise in August.</li>
<li>The University of Michigan consumer sentiment fell to 68.9 in October versus a five-month high level of 70.1 in September, and compared to market estimates of 70.8.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41290782/cvs-has-real-value-jim-cramer-says-micron-had-an-amazing-quarter"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41290782/cvs-has-real-value-jim-cramer-says-micron-had-an-amazing-quarter">CVS Has &#8216;Real Value,&#8217; Jim Cramer Says: Micron Had An &#8216;Amazing&#8217; Quarter</a></li>
</ul>

Gold Gains 1%; Wells Fargo Shares Gain After Q3 Earnings

<h3>Gainers</h3>
<ul>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares increased by 51.8% to $0.91 during Friday's regular session. The market value of their outstanding shares is at $9.2 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock rose 22.41% to $0.3. The market value of their outstanding shares is at $7.0 million. </li>
<li>Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) stock rose 21.29% to $1.88. The company's market cap stands at $512.3 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) stock rose 18.15% to $0.47. The company's market cap stands at $1.5 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock moved upwards by 17.99% to $1.64. The market value of their outstanding shares is at $3.0 million. </li>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) stock increased by 16.08% to $3.68. The company's market cap stands at $97.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) shares fell 13.4% to $11.47 during Friday's regular session. The market value of their outstanding shares is at $773.3 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares declined by 13.37% to $0.51. The company's market cap stands at $2.2 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock decreased by 10.15% to $6.2. The market value of their outstanding shares is at $80.6 million. </li>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares decreased by 9.95% to $3.53. The company's market cap stands at $3.2 million. </li>
<li>Genenta Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTA#NASDAQ">GNTA</a>) shares declined by 9.69% to $6.25. The company's market cap stands at $113.8 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares declined by 9.37% to $1.78. The market value of their outstanding shares is at $87.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CBUS

ENTO

GNTA

HSCS

MNOV

NIVF

NUWE

PTIX

12 Health Care Stocks Moving In Friday's Intraday Session

U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Friday.
Shares of Fastenal Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) rose sharply during Friday's session after the company reported <a href="https://www.benzinga.com/news/earnings/24/10/41290240/fastenal-q3-earnings-revenue-and-eps-beat-sets-cautious-tone-on-2024-outlook">better-than-expected third-quarter financial results.</a>
Fastenal reported sales growth of 3.5% year-over-year to $1.910 billion, beating the consensus of $1.908 billion. Unit sales increased in the quarter due to growth from larger customers, new Onsite locations, and an extra selling day, despite minor disruptions from Hurricane Helene and stable pricing. The company's third-quarter EPS was 52 cents, above the estimate of 51 cents.
Fastenal shares jumped 6% to $74.18 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Torrid Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) shares jumped 13% to $3.78.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) surged 12% to $1.7350 after the company announced it signed a research collaboration agreement with the National Cancer Center of Singapore. The project will use the company&#8217;s sequencing technologies.</li>
<li>Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) gained 11.5% to $30.66.</li>
<li>Digital Turbine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) rose 10.6% to $3.2750.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) gained 10.6% to $10.32.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares jumped 10.4% to $18.92 after the company announced it reported long-term data from its HOPE-2 OLE study for Duchenne muscular dystrophy at the 2024 World Muscle Society Congress. Additionally, HC Wainwright &amp; Co. raised its price target on the stock from $40 to $77.</li>
<li>Nuvation Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NASDAQ">NUVB</a>) gained 9.5% to $2.2000.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) rose 9.1% to $10.36.</li>
<li>Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) gained 8.7% to $13.49 in reaction to Tesla announcing that a rival offering, the Cybercab, will go into production in 2026.</li>
<li>Aehr Test Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) rose 8.6% to $14.47 after the company reported better-than-expected first-quarter financial results.</li>
<li>Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) gained 8.2% to $84.34 in reaction to Tesla announcing that a rival offering, the Cybercab, will go into production in 2026.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) gained 8% to $26.04 on continued upward momentum.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) gained 7.8% to $197.69.</li>
<li>Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) rose 5.6% to $60.98 following upbeat quarterly earnings.</li>
<li>JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) gained 4.6% to $222.57 after reporting strong quarterly results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41270853/jim-cramer-likes-reddit-very-much-calls-accenture-a-great-buy">Jim Cramer Likes Reddit Very Much, Calls Accenture A &#8216;Great Buy&#8217;</a></li>
</ul>

Intraday Update

AEHR

APPS

CAPR

CURV

FAST

LYFT

MESO

MSTR

NUVB

UBER

WOLF

Fastenal Posts Upbeat Earnings, Joins Wells Fargo, JPMorgan And Other Big Stocks Moving Higher On Friday

WIIM

Pacific Biosciences shares are trading higher after the company announced it signed a research collaboration agreement with the National Cancer Center of Singapore. The project will use the company's sequencing technologies.

Biotech

General

PacBio Signs Research Collaboration Agreement With National Cancer Centre of Singapore, Using Co.'s Sequencing Technologies

The HiFi Solves Sub-fertility Consortium, an innovative collaboration involving five leading centers across the Asia-Pacific region, announces work aimed at redefining the landscape of fertility research. Utilizing PacBio HiFi long-read sequencing, the consortium, led by KK Women's and Children's Hospital (KKH) in Singapore, is pioneering the use of PacBio HiFi long-read sequencing to enhance the diagnosis and treatment of subfertility and recurrent miscarriages (RPL). &nbsp;
The HiFi Solves Sub-fertility Consortium integrates DNAstack's federated data platform, the world's first solution to enable the creation and analysis of global federated networks of data in compliance with industry standards set by the Global Alliance for Genomics &amp; Health. This platform allows for seamless global collaboration on complex datasets without the need to move the data, ensuring sensitive genomic information remains secure while supporting efficient analysis and compliance with regional data governance.
Under the leadership of Associate Professor Saumya S. Jamuar, the consortium brings together esteemed experts: Professor Vorasuk Shotelersuk from the Center of Excellence for Medical Genomics, Chulalongkorn University, Thailand; Professor Ming Chen from Changhua Christian Hospital Medical Center, Taiwan; Assistant Professor Jee Soo Lee from Seoul National University College of Medicine (SNUCM) Laboratory Medicine, South Korea; and Associate Professor Sohyun Hwang, CHA Bundang Medical Center, CHA University School of Medicine, South Korea. Together, they are breaking new ground in fertility research with the goal of revolutionizing care for millions affected by subfertility and RPL globally.

Global

PacBio HiFi Long-Read Sequencing Consortium, Led By KK Women's And Children's Hospital In Singapore, Is Pioneering The Use Of PacBio's Technology To Enhance The Diagnosis And Treatment Of Subfertility And Recurrent Miscarriages

U.S. stocks were mixed, with the Nasdaq Composite falling around 150 points on Friday.
Shares of Quanex Building Products Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) rose sharply during Friday's session after the company reported better-than-expected third-quarter financial results and issued <a href="https://www.benzinga.com/quote/NX/earnings">FY24 guidance above estimates.</a>
Quanex Building Prods reported quarterly earnings of 73 cents per share which beat the analyst consensus estimate of 70 cents per share. The company reported quarterly sales of $280.300 million which beat the analyst consensus estimate of $278.457 million.
Quanex Building Products shares jumped 19.9% to $29.80 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Argan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>) gained 28.4% to $91.64 after the company reported better-than-expected second-quarter financial results.</li>
<li>Travere Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) shares rose 15.3% to $11.45 after the company announced it that the FDA has granted full approval to FILSPARI to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. Also, HC Wainwright &amp; Co maintained a Buy rating on the stock and raised its price target from $20 to $23.</li>
<li>Zumiez Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZUMZ#NASDAQ">ZUMZ</a>) rose 15.3% to $29.67 following quarterly results.</li>
<li>Samsara Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) gained 15% to $44.58 after the company reported better-than-expected quarterly financial results and raised its FY25 guidance.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) gained 14.6% to $1.6050.</li>
<li>Guidewire Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) rose 13.9% to $163.94 after the company reported better-than-expected quarterly financial results. Also, Oppenheimer and Baird maintained an Outperform rating on the stock and raised their respective price targets.</li>
<li>Bowlero Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOWL#NYSE">BOWL</a>) climbed 13.5% to $12.25 after the company reported better-than-expected fourth-quarter sales results and issued FY25 revenue guidance above estimates.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) gained 9.7% to $1.4485.</li>
<li>Smartsheet Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMAR#NYSE">SMAR</a>) rose 9.6% to $54.11 following better-than-expected quarterly financial results. The company also raised its FY25 EPS outlook.</li>
<li>Brady Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRC#NYSE">BRC</a>) gained 6.8% to $76.75 after the company reported better-than-expected quarterly adjusted EPS results. Also, the company authorized an additional $100 million of shares for repurchase.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) rose 6% to $5.14 after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $5.30 to $8.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40748814/top-4-financials-stocks-that-may-crash-this-month">Top 4 Financials Stocks That May Crash This Month</a></li>
</ul>

BOWL

GWRE

PSNY

SMAR

TVTX

ZUMZ

Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday

PacBio Partners With University Hospital Of Münster To Advance Male Infertility And Rare Disease Research Using Revio HiFi Long-Read Whole Genome Sequencing System For Accurate Genetic Analysis

5 analysts have shared their evaluations of Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $3.9, a high estimate of $7.00, and a low estimate of $2.00. Observing a downward trend, the current average is 17.89% lower than the prior average price target of $4.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1724857268_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Pacific Biosciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$2.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Ross Osborn</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$3.50</td>
<td>$3.50</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.50</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$4.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Pacific Biosciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pacific Biosciences compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Pacific Biosciences's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Pacific Biosciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PACB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacific Biosciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Pacific Biosciences Better</h2>
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
<h3>Understanding the Numbers: Pacific Biosciences's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Pacific Biosciences faced challenges, resulting in a decline of approximately -24.3% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Pacific Biosciences's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -481.27%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Pacific Biosciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -30.36%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Pacific Biosciences's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -10.9%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Pacific Biosciences's debt-to-equity ratio stands notably higher than the industry average, reaching 1.88. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What 5 Analyst Ratings Have To Say About Pacific Biosciences

Scotiabank analyst Sung Ji Nam maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Sector Outperform and lowers the price target from $8 to $7.

Price Target

Scotiabank Maintains Sector Outperform on Pacific Biosciences, Lowers Price Target to $7

U.S. stock futures were mixed this morning, with the S&amp;P 500 futures falling around 0.1% on Friday.
Shares of Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) declined in today's pre-market trading <a href="https://www.benzinga.com/news/earnings/24/08/40406069/applied-materials-q3-earnings-revenue-beat-eps-beat-demand-being-driven-by-race-for-ai-leadership-a">following third-quarter results.</a>
Applied Materials reported third-quarter revenue of $6.78 billion, beating the consensus estimate of $6.673 billion. The chip equipment company reported adjusted earnings of $2.12 per share, beating analyst estimates of 2.02 per share.
Applied Materials anticipates fourth-quarter revenue of $6.53 billion, plus or minus $400 million, versus estimates of $6.91 billion. The company expects fourth-quarter adjusted earnings to be between $2 and $2.36 per share, versus estimates of $2.14 per share.
Applied Materials shares fell 3.1% to $205.25 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Sonida Senior Living, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDA#NYSE">SNDA</a>) shares dipped 15.4% to $27.06 in today's pre-market trading. Sonida Senior Living priced its upsized public offering of 4.3 million common stock at $27 per share.</li>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) shares declined 6.1% to $5.36 in pre-market trading.</li>
<li>Baytex Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTE#NYSE">BTE</a>) shares fell 5.8% to $3.40 in pre-market trading.</li>
<li>U-BX Technology Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBXG#NASDAQ">UBXG</a>) shares declined 4% to $19.00 in pre-market trading after jumping 45% on Thursday.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) fell 3.5% to $1.63 in pre-market trading after jumping 25% on Thursday.</li>
<li>Amcor plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMCR#NYSE">AMCR</a>) declined 3.1% to $10.51 in pre-market trading following fourth-quarter results.</li>
<li>RLX Technology Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) shares fell 2.5% to $1.58 in pre-market trading following weak quarterly sales.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40394036/jim-cramer-recommends-buying-clorox-ceo-has-done-remarkable-job"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40394036/jim-cramer-recommends-buying-clorox-ceo-has-done-remarkable-job">Jim Cramer Recommends Buying Clorox: &#8216;CEO Has Done Remarkable Job&#8217;</a></li>
</ul>

Pre-Market Outlook

AMAT

AMCR

LUMN

SNDA

UBXG

Applied Materials, Amcor, RLX Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Stephens &amp; Co. analyst Mason Carrico maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Overweight and lowers the price target from $3.5 to $2.5.

Stephens & Co. Maintains Overweight on Pacific Biosciences, Lowers Price Target to $2.5

Analysts' ratings for Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $3.3, a high estimate of $4.00, and a low estimate of $2.00. Experiencing a 37.14% decline, the current average is now lower than the previous average price target of $5.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1723485635_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Pacific Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$2.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Ross Osborn</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$3.50</td>
<td>$3.50</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.50</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$4.00</td>
<td>-</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$4.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pacific Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pacific Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Pacific Biosciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Pacific Biosciences's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PACB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacific Biosciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Pacific Biosciences's Background</h2>
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
<h3>Financial Milestones: Pacific Biosciences's Journey</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Pacific Biosciences's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -7.21% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -481.27%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Pacific Biosciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -30.36%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Pacific Biosciences's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -10.9%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Pacific Biosciences's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.88, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 5 Ratings For Pacific Biosciences

Pacific Biosciences of California share are trading lower after Morgan Stanley lowered its price target on the stock from $4 to $2.

Morgan Stanley analyst Tejas Savant maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Equal-Weight and lowers the price target from $4 to $2.

Morgan Stanley Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $2

Pacific Biosciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NYSE">PACB</a>) short percent of float has risen 9.25% since its last report. The company recently reported that it has 61.68 million shares sold short, which is 26.09% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.87 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Pacific Biosciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723131011_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Pacific Biosciences has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Pacific Biosciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Pacific Biosciences's peer group average for short interest as a percentage of float is 6.60%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Pacific Biosciences's Recent Short Interest

Cantor Fitzgerald analyst Ross Osborn reiterates Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Overweight and maintains $3.5 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Pacific Biosciences, Maintains $3.5 Price Target

Pacific Biosciences of California shares are trading lower after the company reported worse-than-expected Q2 revenue results. Also, Canaccord Genuity maintained a Buy rating on the stock but lowered its price target from $3.5 to $3.

Canaccord Genuity analyst Kyle Mikson maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Buy and lowers the price target from $3.5 to $3.

Canaccord Genuity Maintains Buy on Pacific Biosciences, Lowers Price Target to $3

Analyst Daniel Brennan of TD Cowen maintained a Buy rating on Pacific Biosciences (PACB – Research Report), with a price target of $2.50. Daniel Br...

Pacific Biosciences: A Buy Rating Amidst Recovery and Growth Potential

In a report released today, David Westenberg from Piper Sandler reiterated a Hold rating on Pacific Biosciences (PACB – Research Report), with a pr...

Piper Sandler Keeps Their Hold Rating on Pacific Biosciences (PACB)

Cantor Fitzgerald analyst Ross Osborn reiterated a Buy rating on Pacific Biosciences (PACB – Research Report) today and set a price target of $3.50...

Cantor Fitzgerald Reaffirms Their Buy Rating on Pacific Biosciences (PACB)

Morgan Stanley analyst Tejas Savant reiterated a Hold rating on Pacific Biosciences (PACB – Research Report) today and set a price target of $2.00....

Pacific Biosciences: A Hold Rating Amidst Lowered Revenue and Persistent Market Challenges

Piper Sandler analyst David Westenberg maintained a Hold rating on Pacific Biosciences (PACB – Research Report) today and set a price target of $2....

Piper Sandler Reaffirms Their Hold Rating on Pacific Biosciences (PACB)

Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing

Pacific Biosciences: Cash Rich, Revenue Poor, Still A 'Sell'

In a report released today, Sung Ji Nam from Scotiabank maintained a Buy rating on Pacific Biosciences (PACB – Research Report), with a price targe...

Pacific Biosciences (PACB) Receives a Buy from Scotiabank

It's hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever.

A Biotech Breakout Will Be Led By Small Caps

Interest Rate Regimes And ARKG: Underperformance Explained

ADPT

ARKG

CDNA

CPRX

CRSP

DNLI

EXAS

IONS

NTLA

NTRA

QDEL

RXRX

SDGR

TWST

Press Releases

Singapore's National Precision Medicine (NPM) programme will partner with PacBio to propel HiFi Sequencing in Southeast Asia

PacBio Announces Second Quarter 2024 Financial Results

Emerging Giants: AI-Driven Innovators Under $2 Set to Transform Markets INBS, PRSO, LPSN, PACB, NINE

PacBio to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Health Care

Revio to Power Research in Male Infertility and Rare Disease at Münster University Hospital

PacBio Announces the HiFi Solves Sub-fertility Consortium in Asia Pacific

Management

PacBio Grants Equity Incentive Award to New Employee

PacBio, A*STAR, and Macrogen Unveil State-of-the-Art Lab to Accelerate Genomics Innovation in Singapore

PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024

PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing

INBS

LPSN

NINE

PRSO

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Akoya Biosciences

BioLife Solns

ChromaDex

Codexis

Champions Oncology

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Pacific Biosciences

Intérêt court

Pacific Biosciences (NASDAQ:PACB) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL